Skip to main content
    I

    Inhibikase Therapeutics Inc (IKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.38
    -0.07 (-4.83%)

    Market Cap: $213.21M

    Last updated: Nov 17, 2026 at 4:30 PM ET

    Inhibikase Therapeutics Inc (IKT) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Inhibikase Therapeutics (IKT) has a market cap of $213.21M and an enterprise value of $161.51M. Its share count is up 118.70% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.

    Total Valuation

    Enterprise value is 24.25% below the market cap, as cash exceeds debt.

    Market Cap$213.21M
    Enterprise Value$161.51M
    Latest price (Nov 17, 2026)$1.38

    Key Dates

    The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 24, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 12.81% in the quarter ended Sep 30, 2026 and grew 370.86% a year over 2 years.

    Shares Outstanding196.94M
    Shares Change (YoY)+118.70%
    Shares Change (QoQ)+12.81%
    Share Count Growth (2Y CAGR)+370.86%

    Price Statistics

    The stock is down 9.80% over 52 weeks and trades 25.41% below its 50-day average.

    Beta (1Y)1.66
    52-Week Change-9.80%
    1-Month Change-16.11%
    3-Month Change-43.67%
    6-Month Change-12.10%
    5-Year Change-87.02%
    Total Return (1Y)-9.80%
    Total Return (5Y CAGR)-34.40%
    Return vs SPY (1Y)-25.31%
    Max Drawdown (1Y)-45.24%
    Max Drawdown (3Y)-65.24%
    Sharpe Ratio (1Y)-0.24
    Correlation with SPY (1Y)0.36
    50-Day Average$1.85
    200-Day Average$1.93
    52-Week Range$1.40 to $2.61
    RSI (14 Days)36.4
    Average Volume (20 Days)573.10K

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 15.34x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio15.34x
    Quick Ratio15.34x
    Debt / Equity0.00x
    Interest Coverage13.09x

    Returns and Efficiency

    Return on equity is -36.64% over the last 12 months, against a 5-year average of -70.92%.

    Return on Equity (ROE)-36.64%
    Return on Assets (ROA)-34.29%
    ROE (5Y Average)-70.92%
    ROA (5Y Average)-58.59%
    ROIC (5Y Average)-23.75%

    Scores

    IKT has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Revenue Growth (YoY)-100.00%
    Gross Profit-$36.81K
    Operating Income-$74.90M
    Pretax Income-$69.21M
    Net Income-$69.17M
    Reported EPS (TTM)-$0.40

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 93.58% of the $201.75M in total assets.

    Cash and Equivalents$51.70M
    Total Debt$0
    Net Cash$51.70M
    Net Cash Per Share$0.26
    Working Capital$185.78M
    Shareholder Equity$188.80M
    Book Value Per Share$0.96
    Total Assets$201.75M
    Total Liabilities$12.96M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$49.37M
    FCF Per Share-$0.36

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Growth

    Book Value Per Share Growth (2Y CAGR)-0.45%
    Tangible Book Per Share Growth (2Y CAGR)-0.45%

    Revenue and profit by year

    Dividends and Yields

    IKT does not pay a dividend.

    Buyback Yield-58.74%
    Shareholder Yield-58.74%

    Stock Splits

    The last split was a 1-for-6 reverse split on Jun 30, 2023.

    Last Split DateJun 30, 2023
    Split TypeReverse split
    Split Ratio1:6

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About IKT

    What is IKT's market cap?

    Inhibikase Therapeutics has a market cap of $213.21M. Its enterprise value, which adds debt and subtracts cash, is $161.51M.

    How many shares of IKT are outstanding?

    Inhibikase Therapeutics has 196.94M shares outstanding. The count is up 118.70% from a year earlier.

    Does IKT pay a dividend?

    No. Inhibikase Therapeutics does not pay a dividend.

    How much debt does IKT have?

    Inhibikase Therapeutics has $0 of total debt and $51.70M of cash and equivalents, a net cash position of $51.70M.